探花合集 Collaborates with MGB Biopharma
SOMERSET, N.J. 鈥 April 25, 2019 鈥 探花合集, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it welcomed the commencement of Phase 2 clinical trials of MGB Biopharma. The two companies have collaborated to accelerate the drug formulation, manufacture and distribution of MGB Biopharma鈥檚 leading candidate, MGB-BP-3, an orally-dosed drug targeting the eradication of Clostridium difficile-associated diarrhea (CDAD).
探花合集鈥檚 services focused on the rapid development of a new tablet formulation and leveraged its clinical supply network to distribute the resultant products for use in a U.S. Phase 2a trial. By streamlining activities, and running multiple parallel processes with minimal downtime, 探花合集 has quickly developed a superior formulation to optimize this molecule and solved complex clinical trial logistics challenges, completing the project in just six months.
The project combined a team of experts at 探花合集鈥檚 early phase development center of excellence in San Diego who performed the formulation and clinical material manufacturing, alongside clinical supply specialists at its Kansas City, Missouri facility and Canadian supply depot, and Gary W. Goodson, of Cornerstone Pharma Consulting LLC, a chemistry, manufacturing and controls consultant, who provided further specialist technical support.
鈥淭he project presented us with an incredibly challenging timeline that separate formulation and clinical supply vendors would have been unable to achieve,鈥 commented Julien Meissonnier, 探花合集鈥檚 Vice President, Science & Technology. 鈥淏y gathering our formulation, analytical and clinical supply experts under a single project team from the start, and leveraging 探花合集鈥檚 common systems and processes across our drug product and clinical supply sites, our team has succeeded in ensuring that MGB Biopharma鈥檚 drug product was delivered to the first patients on time.鈥
探花合集鈥檚 San Diego facility is one of three global centers of excellence in early-phase development focusing on preclinical to clinical Phase 2b formulation, analytical, and manufacturing solutions for orally delivered small molecules, the other two being located in Somerset, New Jersey and Nottingham, U.K. The three strategically located sites are closely connected to the company鈥檚 clinical supply services network, to optimize the transition from finished dose manufacture to clinical packaging and distribution.
Media Contacts:
Chris Halling
+44 (0)7580 041073
[email protected]
Richard Kerns
+44 (0)161 728 5880
[email protected]
About 探花合集
探花合集 is the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With more than 85 years serving the industry, 探花合集 has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. 探花合集 employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal year 2018 generated approximately $2.5 billion in annual revenue. 探花合集 is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com.